Original Article
Leukemia (2008) 22, 313–322; doi:10.1038/sj.leu.2405030; published online 22 November 2007
Marrow fibrosis predicts early fatal marrow failure in patients with myelodysplastic syndromes
G Buesche1, H Teoman1, W Wilczak2, A Ganser3, H Hecker4, L Wilkens5,6, G Göhring5, B Schlegelberger5, O Bock1, A Georgii1 and H Kreipe1
- 1Institut für Pathologie, Medizinische Hochschule Hannover, Hannover, Germany
- 2Institut für Pathologie, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany
- 3Klinik für Hämatologie, Hämostaseologie und Onkologie, Medizinische Hochschule Hannover, Hannover, Germany
- 4Institut für Biometrie, Medizinische Hochschule Hannover, Hannover, Germany
- 5Institut für Zell- und Molekularpathologie, Medizinische Hochschule Hannover, Hannover, Germany
- 6Institut für Pathologie, Universität Bern, Bern, Switzerland
Correspondence: Dr med. G Buesche, Institut für Pathologie, Medizinische Hochschule Hannover, Carl-Neuberg-Str. 1, Hannover D-30625, Germany. E-mail: guntram.buesche@arcor.de
Received 31 July 2007; Revised 9 October 2007; Accepted 10 October 2007; Published online 22 November 2007.
Abstract
Marrow fibrosis (MF) has rarely been studied in myelodysplastic syndromes (MDS). There are no data on occurrence and significance of MF in the context of the World Health Organization (WHO) classification of disease. In total, 349 bone marrow biopsies from 200 patients with primary MDS were examined for MF and its prognostic relevance. MF correlated with multilineage dysplasia, more severe thrombopenia, higher probability of a clonal karyotype abnormality, and higher percentages of blasts in the peripheral blood (P<0.002). Its frequency varied markedly between different MDS types ranging from 0 (RARS) to 16% (RCMD, RAEB, P<0.007). Two patients with MF showed a Janus kinase-2 mutation (V617F). Patients with MF suffered from marrow failure significantly earlier with shortening of the survival time down to 0.5 (RAEB-1/-2), and 1–2 (RCMD, RA) years in median (P<0.00005). The prognostic relevance of MF was independent of the International Prognostic Scoring System and the classification of disease. Conclusion: The risk of MF Differs markedly between various subtypes of MDS. MF indicates an aggressive course with a significantly faster progression to fatal marrow failure and should therefore be considered in diagnosis, prognosis and treatment of disease.
Keywords:
myelodysplastic syndromes, marrow fibrosis, WHO classification, IPSS, prognosis
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated
RESEARCH
Journal of Cerebral Blood Flow & Metabolism Original Article
Journal of Cerebral Blood Flow & Metabolism Original Article
Marrow fibrosis predicts early fatal marrow failure in patients with myelodysplastic syndromes
Leukemia Original Article
Leukemia Original Article
